Disruption of the programmed cell death protein 1 (PD-1) pathway with immune checkpoint
inhibitors represents a major breakthrough in the treatment of non–small cell lung cancer.
We hypothesized that combined inhibition of C5a/C5aR1 and PD-1 signaling may have a
synergistic antitumor effect. The RMP1-14 antibody was used to block PD-1, and an L-
aptamer was used to inhibit signaling of complement C5a with its receptors. Using
syngeneic models of lung cancer, we demonstrate that the combination of C5a and PD-1 …